Posted by Michael Wonder on 05 Feb 2020
WPD Pharmaceuticals’ annamycin drug received FDA approval of fast track designation
5 February 2020 - WPD Pharmaceuticals is pleased to provide an update on its annamycin drug.
Through its development partner, Moleculin Biotech, annamycin received approval from the U.S. FDA for fast track designation.
Annamycin is currently being studied for the treatment of relapsed or refractory acute myeloid leukaemia.
Read WPD Pharmaceuticals press release
